Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1HC9R)

Drug Name

MGL-3196 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Familial hypercholesterolemia	5C80.00	Phase 2	[1]
Hypercholesterolaemia	5C80.0	Phase 1	[2]
Hyperlipidaemia	5C80	Phase 1	[3]

Cross-matching ID

PubChem CID: 15981237
CAS Number: CAS 920509-32-6
TTD Drug ID: DM1HC9R

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Thyroid hormone receptor beta (THRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextrothyroxine Sodium	DMBVEC7	High blood cholesterol level	5C80.00	Approved	[4]
BCT303	DMUFY4K	Hypothyroidism	5A00	Phase 2	[5]
MB-07811	DM6JTSZ	Hyperlipidaemia	5C80	Phase 2	[6]
VK-2809	DMY5NUR	Hypercholesterolaemia	5C80.0	Phase 2	[1]
ZYT-1	DM1XOZK	Lipid metabolism disorder	5C52.Z	Phase 1	[5]
Axitirome	DM6L5IP	Hyperlipidaemia	5C80	Phase 1	[7]
VK-0214	DM90GS3	X-linked Adrenoleukodystrophy	5C57	Phase 1	[8]
tiratricol	DMZO6CV	Wound healing	EL8Y	Clinical trial	[9]
Cacodylate Ion	DMK4XLD	Discovery agent	N.A.	Investigative	[10]
3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one	DM2JBQI	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thyroid hormone receptor beta (THRB)	TTGER3L	THB_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT01367873) Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects. U.S. National Institutes of Health.
3	Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 589).
7	Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors alpha-1 and beta-1. FEBS Open Bio. 2012; 2: 247-253.
8	Clinical pipeline report, company report or official report of Viking Therapeutics
9	Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34.
10	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11	Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.